.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Johnson and Johnson
Queensland Health
Chubb
Baxter
Daiichi Sankyo
Novartis
Citi
UBS
Boehringer Ingelheim

Generated: December 16, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 019157

« Back to Dashboard

NDA 019157 describes PEDIAPRED, which is a drug marketed by Seton Pharm and is included in one NDA. It is available from two suppliers. Additional details are available on the PEDIAPRED profile page.

The generic ingredient in PEDIAPRED is prednisolone sodium phosphate. There are eighty-six drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the prednisolone sodium phosphate profile page.

Summary for 019157

Tradename:1
Applicant:1
Ingredient:1
Patents:0
Therapeutic Class:Hormonal Agents, Stimulant/Replacement/Modifying (Adrenal)
Inflammatory Bowel Disease Agents
Ophthalmic Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 019157

Suppliers and Packaging for NDA: 019157

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
PEDIAPRED prednisolone sodium phosphate SOLUTION;ORAL 019157 NDA Seton Pharmaceuticals, LLC 13925-166 13925-166-04 120 mL in 1 BOTTLE (13925-166-04)
PEDIAPRED prednisolone sodium phosphate SOLUTION;ORAL 019157 NDA Royal Pharmaceuticals 68791-104 68791-104-04 120 mL in 1 BOTTLE (68791-104-04)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;ORALStrengthEQ 5MG BASE/5ML
Approval Date:May 28, 1986TE:AARLD:Yes

Expired Orange Book Patents for NDA: 019157

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Seton PharmPEDIAPREDprednisolone sodium phosphateSOLUTION;ORAL019157-001May 28, 1986► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
Cipla
Johnson and Johnson
Harvard Business School
Baxter
UBS
Julphar
Boehringer Ingelheim
Medtronic
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot